Molecular Biology & Nanomedicine (Aug 2020)
Drug-Eluting Stent Implantation after Percutaneous Transluminal Angioplasty decreases Restenosis Incidence and Inflammatory Reaction in Patients with Lower Extremity Arterial Disease
Abstract
Lower extremity arterial disease (LEAD) is considered as a common cause resulting the narrowing in the vessels of the lower limbs. This study investigated effect of drug-eluting stent (DES) implantation after percutaneous transluminal angioplasty (PTA) on restenosis incidence in patients with LEAD.The patients with LEAD in control group received PTA alone, and the patients in intervention group received PTA and DES implantation. Skin temperature, transcutaneous oxygen tension (TcPO2), ankle brachial index (ABI), recurrence rate, total response rate, ulcer cure and improvement rates and restenosis incidence 6 months and 12 months after treatment were compared. Clinical symptoms, signs, and foot ulcer condition before and after treatment were compared. Enzyme-linked immunosorbent assay (ELISA) was used to detect the level of like interleukin 6 (IL-6), tumor necrosis factor α (TNF-α) andC-reactive protein (CRP) 3 d and 6 months. Six months after treatment, the patients in intervention group showed increased TcPO2 and ABI and ulcer cure rate but decreased restenosis incidence, and 12 months after treatment, the patients in intervention group exhibited increased skin temperature, TcPO2 and ABI but decreased recurrence rate and restenosis incidence. Moreover, compared with the control group, total response rate, symptoms, signs and foot ulcer condition were increased, but the levels of IL-6, TNF-α and CRP decreased 3 d and 6 months in the intervention group. The total effective rate of restenosis after LEAD intervention was associated with treatment regimen, Fontaine staging, and Hb A1c. Collectively, DES implantation after PTA decreases restenosis incidence and inflammatory reaction in LEAD patients compared with PTA alone.
Keywords
